Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) was upgraded by investment analysts at B. Riley to a "strong-buy" rating in a research report issued to clients and investors on Thursday,Zacks.com reports.
Other equities research analysts have also recently issued reports about the stock. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday. HC Wainwright increased their price target on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, January 6th.
Check Out Our Latest Stock Report on Eton Pharmaceuticals
Eton Pharmaceuticals Trading Up 11.9 %
ETON stock traded up $1.43 during trading on Thursday, hitting $13.44. The company had a trading volume of 357,269 shares, compared to its average volume of 373,645. The stock has a market cap of $350.13 million, a PE ratio of -61.09 and a beta of 1.38. The business has a 50-day moving average of $11.74 and a 200-day moving average of $7.45. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00.
Institutional Investors Weigh In On Eton Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the third quarter valued at approximately $90,000. Renaissance Technologies LLC increased its holdings in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock valued at $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. 27.86% of the stock is owned by institutional investors.
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Featured Stories
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
